Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease
- Friday, October 15, 2021, 7:00
- Finance
- Add a comment
BOSTON, Oct. 15, 2021 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that Health Canada has approved FERRIPROX® (deferiprone) for the treatment of iron overload…
About the Author
adminasapcorp has written 41802 stories on this site.